Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.02 EUR | +1.25% | -1.46% | +7.16% |
15/04 | Faron Pharmaceuticals reappoints former finance chief on interim basis | AN |
14/02 | Biohit Oyj Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 15.3M 16.36M 1.36B | Sales 2025 * | 17.4M 18.6M 1.55B | Capitalization | 30.65M 32.77M 2.73B |
---|---|---|---|---|---|
Net income 2024 * | 1M 1.07M 89.18M | Net income 2025 * | 2M 2.14M 178M | EV / Sales 2024 * | 1.45 x |
Net cash position 2024 * | 8.4M 8.98M 749M | Net cash position 2025 * | 10M 10.69M 892M | EV / Sales 2025 * | 1.19 x |
P/E ratio 2024 * |
15.5
x | P/E ratio 2025 * |
15.5
x | Employees | 46 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 42.47% |
1 day | +1.25% | ||
1 week | -1.46% | ||
Current month | +1.00% | ||
1 month | +3.06% | ||
3 months | +6.04% | ||
6 months | +4.66% | ||
Current year | +7.16% |
Managers | Title | Age | Since |
---|---|---|---|
Jussi Hahtela
CEO | Chief Executive Officer | 51 | 04/21/04 |
Jussi Sorvo
DFI | Director of Finance/CFO | 34 | 01/21/01 |
Panu Hendolin
CTO | Chief Tech/Sci/R&D Officer | 53 | 01/22/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 56 | 14/23/14 | |
Founder | 81 | 01/88/01 | |
Director/Board Member | 73 | 24/19/24 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 2.02 | +1.25% | 3,866 |
25/24/25 | 1.995 | -0.75% | 985 |
24/24/24 | 2.01 | -0.50% | 2,634 |
23/24/23 | 2.02 | -0.98% | 22,615 |
22/24/22 | 2.04 | -0.49% | 8,953 |
Delayed Quote Nasdaq Helsinki, April 26, 2024 at 08:15 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.16% | 32.72M | |
+7.13% | 7.91B | |
-3.15% | 4.66B | |
-9.18% | 2.84B | |
+1.11% | 2.03B | |
-26.56% | 1.12B | |
-22.71% | 759M | |
-13.49% | 755M | |
-56.85% | 682M | |
-24.66% | 671M |
- Stock Market
- Equities
- BIOBV Stock